Please complete the CAPTCHA to continue
@akstonbio.com
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
David Alleva is listed as Chief Scientific Officer at Diamune Therapeutics at Diamune Therapeutics, based in Boston, Massachusetts, United States. AeroLeads shows a work email signal at akstonbio.com and a matched LinkedIn profile for David Alleva.
David Alleva previously worked as Chief Scientific Officer at Diamune Therapeutics and President at Immucrine Biopharma Consulting, Llc. David Alleva holds Ph.D., Immunology from Virginia Tech.
This section adds company-level context without repeating David Alleva's masked contact details.
AeroLeads found 1 current-domain work email signal for David Alleva. Compare company email patterns before reaching out.
A successful scientific leader and manager in the biopharmaceutical industry with a strong background in Immunology/Pharmacology, Autoimmunity (Type 1 diabetes), and Vaccinology with management strengths in Immunotherapeutic Discovery and Development (discovery/preclinical through clinical Ph2), Translational Research, and Assay Development.20+ yrs experience in drug discovery/development and translation of therapeutics (small-molecule and biologics) and vaccines in autoimmune, inflammatory, metabolic, angiogenic/oncology, and infectious disease areas. Built extensive network of firsthand professional relationships with key opinion leaders. Strong in leadership/management of scientific teams, in creation of departments, and in development of start-up biotech companies. Excellent publication record.
Listed skills include Drug Discovery, Immunology, Biotechnology, Assay Development, and 27 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Diamune is a biotech company developing novel therapeutics for the Prevention and Treatment of Type 1 Diabetes. Its innovative IgG Fc-Fusion insulin analogs are meticulously engineered to prevent autoimmune diabetes via immune modulation in pre-diabetic individuals, while others are designed as a “once-a-week” Ultra Long-Acting Insulin treatment to elevate standards of diabetes management.
• Two decades of experience and success in the biopharma industry and academic research environments that includes an extensive network of first-hand professional relationships with key opinion leaders• Provides scientific and business expertise with start-up biotech companies in drug discovery/development of immunology- & inflammation-based therapeutics, especially those for autoimmune diseases with emphasis on type 1 diabetes• Creates therapeutic development and business plans suitable for generating investment funds by constructing value propositions that support a practical goal-oriented plan.- Establishes therapeutic development strategic and tactical plan (therapeutic rationale, preclinical structure, clinical progression)- Develops business plan including financials, management design, value inflection timeline - Develops and executes funding strategy (e.g., facilitate clinical support from consortia)• Creates and presents pitch deck with company management to funding organizations• Non-dilutive financing: Prepares Grant proposals (NIH SBIR and foundation grants)
A biotech start-up focused on a novel vaccine delivery system
Woburn, Massachusetts, Us
IM Therapeutics is a clinical-stage company pioneering personalized, oral medicines that target human leukocyte antigen (HLA) gene variants to treat the root cause of autoimmune diseases.
Beverly, Massachusetts, Us
Akston Biosciences Corporation is a leader in the field of insulin engineering and COVID-19 vaccine development. The company was founded in 2011 by the former SmartCells, Inc. team who developed the world’s first clinical glucose-responsive insulin (acquired by Merck & Co. in 2010). Combining its core expertise with modern biotechnology manufacturing techniques, Akston is developing new classes of biologic therapeutics for use in autoimmune Type 1 diabetes prevention, ultra-long acting insulin therapy, and oncology to dramatically improve both human and animal health. In addition, its core Fc-fusion protein technology and GMP production facility is facilitating development of a novel COVID-19 vaccine.
New York, New York, Us
• At the Juvenile Diabetes Research Foundation (JDRF), led the type 1 diabetes (T1D) immunotherapies program and portfolio that drove a therapeutic research and development pipeline aimed at delivering novel Immune Modulation therapies for the prevention and treatment of T1D• Created and executed strategies for developing effective and innovative immunotherapies for T1D, including partnering with biotechnology and pharmaceutical companies and managing an academic research portfolio (leveraging experiences with therapies from other autoimmune indications)• Translational research/medicine: Developed Biomarker discovery and assay development initiatives• Organizational leadership: created and implemented portfolio analysis system for evaluating and measuring progress and success within program areas.
Working with companies seeking government contracts for scientific-oriented projects, including IT Cloud technology contracts for genomics research, and R&D contracts for biodefense vaccines. Provide scientific education and advice, and contribute to the preparation of contract proposals to RFPs.
Gaithersburg, Maryland, Us
Leading an immunology research and development group of scientists in infectious disease vaccine development.
Quick answers generated from the profile data available on this page.
David Alleva works for Diamune Therapeutics.
David Alleva is listed as Chief Scientific Officer at Diamune Therapeutics at Diamune Therapeutics.
AeroLeads has found 1 work email signal at @akstonbio.com for David Alleva at Diamune Therapeutics.
David Alleva is based in Boston, Massachusetts, United States while working with Diamune Therapeutics.
David Alleva has worked for Diamune Therapeutics, Immucrine Biopharma Consulting, Llc, Evantigen, Inc., Im Therapeutics, and Akston Biosciences Corporation.
You can use AeroLeads to view verified contact signals for David Alleva at Diamune Therapeutics, including work email, phone, and LinkedIn data when available.
David Alleva holds Ph.D., Immunology from Virginia Tech.
David Alleva is listed with skills including Drug Discovery, Immunology, Biotechnology, Assay Development, Drug Development, Clinical Development, Pharmaceutical Industry, and In Vitro.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts